You can buy or sell MYGN and other stocks, options, and ETFs commission-free!
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through the Diagnostics and Other segments.
Paul J. Diaz
Salt Lake City, Utah
52 Week High
52 Week Low
Recap: Myriad Genetics Q3 Earnings
Shares of Myriad Genetics (NASDAQ:MYGN) remained flat in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share rose
-$0.14 per share
-$0.06 per share